Alpha Crest Capital Management LLC Uni Qure N.V. Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $227,141 - $341,648	13,377 New	13,377 $251,000
Q1 2022 May 12, 2022	SELL	$14.54 - $21.5 $732,990 - $1.08 Million	-50,412 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$20.24 - $36.01 $374,237 - $665,824	-18,490 Reduced 26.84%	50,412 $1.05 Million
Q3 2021 Nov 10, 2021	BUY	$26.01 - $38.22 $1.79 Million - $2.63 Million	68,902 New	68,902 $2.21 Million
Q1 2021 May 13, 2021	SELL	$29.24 - $42.03 $321,640 - $462,330	-11,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$35.35 - $50.67 $388,850 - $557,370	11,000 New	11,000 $397,000
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $395,779 - $524,259	-11,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$45.06 - $67.74 $108,144 - $162,576	2,400 Added 27.91%	11,000 $496,000
Q1 2020 May 13, 2020	BUY	$40.01 - $73.97 $344,086 - $636,142	8,600 New	8,600 $408,000
Q4 2019 Feb 12, 2020	SELL	$37.13 - $74.62 $319,318 - $641,732	-8,600 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$39.36 - $76.8 $338,496 - $660,480	8,600 New	8,600 $338,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.